Employers are rethinking coverage for weight-loss drugs as the cost of GLP-1 medications puts growing pressure on workplace health plans. While demand for treatments like Ozempic and Wegovy continues to rise, many companies are weighing affordability, long-term benefits, and the limits of what employer-sponsored insurance can cover.
This episode explores why some employers are cutting back on weight-loss drug coverage, how benefit managers and insurers are responding, and what the shift could mean for workers, healthcare costs, and the future of obesity treatment access.
Podcast: Play in new window | Download
